Compare Abbott Laboratories (ABT) vs Block Inc (XYZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Block Inc — how do they compare? Abbott Laboratories trades at $95.33 (market cap $166.94B), while Block Inc trades at $76.35 (market cap $46.16B). The key difference: Abbott Laboratories is far larger — about 3.6× Block Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Block Inc pays none. Which is the better fit depends on your goals.
| ABT | XYZ | |
|---|---|---|
Market Cap | $166.94B | $46.16B |
Sector | Health | Technology |
52-Week High | $136.62 | $81.11 |
52-Week Low | $82.57 | $49.04 |
Enterprise Value | $193.69B | $41.03B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
XYZ (Block, Inc.) trades at $77.56, down 1.61% today, with a bullish technical signal from moving averages and strong analyst consensus (74% buy ratings). Recent earnings show mixed results with Q1 2026 beating expectations, while cash flow turned negative in 2025 due to heavy investing. The company continues expanding its Square platform through AI integrations and enterprise partnerships, positioning for growth in digital payments.
Outlook remains positive with a $87.71 consensus price target, though high P/E of 61.66 and declining net income margins pose valuation concerns. Key risks include execution on AI initiatives and competitive pressure in fintech. Institutional sentiment is supportive, but investors should monitor Q2 2026 earnings due August 5, 2026 for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
